Across TCGA pan-cancer cohorts, IGKV6D-21 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IGKV6D-21 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher IGKV6D-21 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGKV6D-21 expression acts as an unfavorable survival marker.

STAD, LUAD, and SKCM are the cancer types where IGKV6D-21 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.001	0.688	<.001	48	view →
LUAD	OS	Median	All	0.338	0.834	.004	12	view →
SKCM	DFS	Median	II,III,IV	0.040	0.683	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: IGKV6D-21 tumor-vs-normal RNA expression · all IGKV6D-21 data types